Page 87 - Read Online

De Mattia et al. Cancer Drug Resist 2019;2:116-30 I http://dx.doi.org/10.20517/cdr.2019.04 Page 129

2003;18:218-21.
33. Boisdron-Celle M, Capitain O, Faroux R, Borg C, Metges JP, et al. Prevention of 5-fluorouracil-induced early severe toxicity by
pre-therapeutic dihydropyrimidine dehydrogenase deficiency screening: assessment of a multiparametric approach. Semin Oncol
2017;44:13-23.
34. Terrazzino S, Cargnin S, Del Re M, Danesi R, Canonico PL, et al. DPYD IVS14+1G>A and 2846A>T genotyping for the prediction of
severe fluoropyrimidine-related toxicity: a meta-analysis. Pharmacogenomics 2013;14:1255-72.
35. Falvella FS, Cheli S, Martinetti A, Mazzali C, Iacovelli R, et al. DPD and UGT1A1 deficiency in colorectalcancerpatientsreceivingtriple
tchemotherapy with fluoropyrimidines, oxaliplatin and irinotecan. Br J Clin Pharmacol 2015;80:581-8.
36. Madi A, Fisher D, Maughan TS, Colley JP, Meade AM, et al. Pharmacogenetic analyses of 2183 patients with advanced colorectal
cancer; potential role for common dihydropyrimidine dehydrogenase variants in toxicity to chemotherapy. Eur J Cancer 2018;102:31-9.
37. Pellicer M, García-González X, García MI, Blanco C, García-Alfonso P, et al. Use of exome sequencing to determine the full profile
of genetic variants in the fluoropyrimidine pathway in colorectal cancer patients affected by severe toxicity. Pharmacogenomics
2017;18:1215-23.
38. Ruzzo A, Graziano F, Galli F, Galli F, Rulli E, et al. Dihydropyrimidinedehydrogenase pharmacogenetics for predicting
fluoropyrimidine-related toxicity in the randomised, phase III adjuvant TOSCA trial in high-risk colon cancer patients. Br J Cancer
2017;117:1269-77.
39. Rosmarin D, Palles C, Church D, Domingo E, Jones A, et al. Genetic markers of toxicity from capecitabine and other fluorouracil-based
regimens: investigation in the QUASAR2 study, systematic review, and meta-analysis. J Clin Oncol 2014;32:1031-9.
40. Offer SM, Wegner NJ, Fossum C, Wang K, Diasio RB. Phenotypic profiling of DPYD variations relevant to 5-fluorouracil sensitivity
using real-time cellular analysis and in vitro measurement of enzyme activity. Cancer Res 2013;73:1958-68.
41. He YF, Wei W, Zhang X, Li YH, Li S, et al. Analysis of the DPYD gene implicated in 5-fluorouracil catabolism in Chinese cancer
patients. J Clin Pharm Ther 2008;33:307-14.
42. Offer SM, Fossum CC, Wegner NJ, Stuflesser AJ, Butterfield GL, et al. Comparative functional analysis of DPYD variants of potential
clinical relevance to dihydropyrimidine dehydrogenase activity. Cancer Res 2014;74:2545-54.
43. Nie Q, Shrestha S, Tapper EE, Trogstad-Isaacson CS, Bouchonville KJ, et al. Quantitative contribution of rs75017182 to
dihydropyrimidine dehydrogenase mRNA splicing and enzyme activity. Clin Pharmacol Ther 2017;102:662-70.
44. Launay M, Dahan L, Duval M, Rodallec A, Milano G, et al. Beating the odds: efficacy and toxicity of dihydropyrimidine
dehydrogenase-driven adaptive dosing of 5-FU in patients with digestive cancer. Br J Clin Pharmacol 2016;81:124-30.
45. Launay M, Ciccolini J, Fournel C, Blanquicett C, Dupuis C, et al. Upfront DPD deficiency detection to secure 5-FU administration: part
2-application to head-and-neck cancer patients. Clin Cancer Drugs 2017;4:122-8.
46. Meulendijks D, Henricks LM, Jacobs BAW, Aliev A, Deenen MJ, et al. Pretreatment serum uracil concentration as a predictor of severe
and fatal fluoropyrimidine-associated toxicity. Br J Cancer 2017;116:1415-24.
47. Etienne-Grimaldi MC, Boyer JC, Beroud C, Mbatchi L, van Kuilenburg A, et al. New advances in DPYD genotype and risk of severe
toxicity under capecitabine. PLoS One 2017;12:e0175998.
48. Botticelli A, Onesti CE, Strigari L, Occhipinti M, Di Pietro FR, et al. A nomogram to predict 5-fluorouracil toxicity:
whenpharmacogenomicsmeets the patient. Anticancer Drugs 2017;28:55-6.
49. Meulendijks D, Rozeman EA, Cats A, Sikorska K, Joerger M, et al. Pharmacogenetic variants associated with outcome in patients with
advanced gastric cancer treated with fluoropyrimidine and platinum-based triplet combinations: a pooled analysis of three prospective
studies. Pharmacogenomics J 2017;17:441-51.
50. Cecchin E, Russo A, Campagnutta E, Martella L, Toffoli G. Lack of association of CYP1 B1*3 polymorphism and ovarian cancer in a
Caucasian population. Int J Biol Markers 2004;19:160-3.
51. Longley DB, Harkin DP, Johnston PG. 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 2003;3:330-8.
52. De Mattia E, Cecchin E, Toffoli G. Pharmacogenomics of intrinsic and acquired pharmacoresistance in colorectal cancer: toward
targeted personalized therapy. Drug Resist Updat 2015;20:39-70.
53. Lima A, Azevedo R, Sousa H, Seabra V, Medeiros R. Current approaches for TYMS polymorphisms and their importance in molecular
epidemiology and pharmacogenetics. Pharmacogenomics 2013;14:1337-51.
54. Jennings BA, Kwok CS, Willis G, Matthews V, Wawruch P, et al. Functional polymorphisms of folate metabolism and response to
chemotherapy for colorectal cancer, a systematic review and meta-analysis. Pharmacogenet Genomics 2012;22:290-304.
55. Campbell JM, Stephenson MD, Bateman E, Peters MDJ, Keefe DM, et al. Irinotecan-induced toxicity pharmacogenetics: an umbrella
review of systematic reviews and meta-analyses. Pharmacogenomics J 2017;17:21-8.
56. Smyth E, Zhang S, Cunningham D, Wotherspoon A, Soong R, et al. Pharmacogenetic analysis of the UK MRC (Medical Research
Council) MAGIC trial: association of polymorphisms with toxicity and survival in patients treated with perioperative epirubicin,
cisplatin, and 5-fluorouracil (ECF) chemotherapy. Clin Cancer Res 2017;23:7543-9.
57. Tan BR, Thomas F, Myerson RJ, Zehnbauer B, Trinkaus K, et al. Thymidylate synthase genotype-directed neoadjuvant chemoradiation
for patients with rectal adenocarcinoma. J Clin Oncol 2011;29:875-83.
58. Rosmarin D, Palles C, Pagnamenta A, Kaur K, Pita G, et al. A candidate gene study of capecitabine-related toxicity in colorectal cancer
identifies new toxicity variants at DPYD and a putative role for ENOSF1 rather than TYMS. Gut 2015;64:111-20.
59. García-González X, Cortejoso L, García MI, García-Alfonso P, Robles L, et al. Variants in CDA and ABCB1 are predictors of
capecitabine-related adverse reactions in colorectal cancer. Oncotarget 2015;6:6422-30.
60. Cecchin E, Agostini M, Pucciarelli S, De Paoli A, Canzonieri V, et al. Tumor response is predicted by patient genetic profile in rectal